Study of SWA1211 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new oral drug, SWA1211, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has spread or cannot be removed, and standard treatments have stopped working or are not an option.
- You must be between 18 and 75 years old.
- You must be able to take care of yourself (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver, heart) must be within certain limits.
- You must have at least one tumor that can be measured or seen on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
This study tests a new drug called HS-20124 for people with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and how well it works.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This early-phase trial tests a new investigational drug (HMPL-415S1) in people with advanced solid tumors that have limited treatment options. It aims to see how the drug is tolerated and whether it can shrink tumors, especially in cases with KRAS-pathway changes.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.